APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
In most colorectal cancers, Wnt/β-catenin signaling is activated by loss-of-function mutations in the adenomatous polyposis coli (APC) gene and plays a critical role in tumorigenesis. Tankyrases poly(ADP-ribosyl)ate and destabilize Axins, a negative regulator of β-catenin, and upregulate β-catenin signaling. Tankyrase inhibitors downregulate β-catenin and are expected to be promising therapeutics for colorectal cancer. However, colorectal cancer cells are not always sensitive to tankyrase inhibitors, and predictive biomarkers for the drug sensitivity remain elusive. Here we demonstrate that the short-form APC mutations predict the sensitivity of colorectal cancer cells to tankyrase inhibitors. By using well-established colorectal cancer cell lines, we found that tankyrase inhibitors downregulated β-catenin in the drug-sensitive, but not resistant, colorectal cancer cells. The drug-sensitive cells showed higher Tcf/LEF transcriptional activity than the resistant cells and possessed “short” truncated APCs lacking all seven β-catenin-binding 20-amino acid repeats (20-AARs). In contrast, the drug-resistant cells possessed “long” APC retaining two or more 20-AARs. Knockdown of the long APCs with two 20-AARs increased β-catenin, Tcf/LEF transcriptional activity and its target gene AXIN2 expression. Under these conditions, tankyrase inhibitors were able to downregulate β-catenin in the resistant cells. These results indicate that the long APCs are hypomorphic mutants, whereas they exert a dominant-negative effect on Axin-dependent β-catenin degradation caused by tankyrase inhibitors. Finally, we established 16 patient-derived colorectal cancer cells and confirmed that the tankyrase inhibitor–responsive cells harbor the short-form APC mutations. These observations exemplify the predictive importance of APC mutations, the most common genetic alteration in colorectal cancers, for molecular targeted therapeutics. Mol Cancer Ther; 16(4); 752–62. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wnt signalling and its impact on development and cancer
Klaus, A., & Birchmeier, W. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2389 · Cited by 1,595 · cited 1×
“These mice produce a short APC (1-580) mutant, which lacks all 20-AARs and is classified as tankyrase inhibitor–sensitive, according to our present study.”
BackgroundAPC, Signal transduction and genetic instability in colorectal cancer
Fodde, R., Smits, R., & Clevers, H. (2001) · Nature Reviews Cancer · doi:10.1038/35094067 · Cited by 937 · cited 2×
“Loss-of-function mutations in adenomatous polyposis coli (APC) gene, a negative regulator of Wnt/b-catenin signaling, frequently occur in colorectal cancer (1, 2).”
BackgroundWnt Signaling through Inhibition of β-Catenin Degradation in an Intact Axin1 Complex
Li, V. S. W., Ng, S. S., Boersema, P. J., Low, T. Y., Karthaus, W. R., Gerlach, J. P., Mohammed, S., Heck, A. J. R., Maurice, M. M., Mahmoudi, T., et al. (2012) · Cell · doi:10.1016/j.cell.2012.05.002 · Cited by 889
The Roles of APC and Axin Derived from Experimental and Theoretical Analysis of the Wnt Pathway
Lee, E., Salic, A., Krüger, R., Heinrich, R., & Kirschner, M. W. (2003) · PLoS Biology · doi:10.1371/journal.pbio.0000010 · Cited by 708 · cited 2×
“Axins serve as a master scaffold for the b-catenin degradation complex and are the rate-limiting factor of b-catenin degradation (35).”
BackgroundThe APC tumour suppressor has a nuclear export function
Rosin-Arbesfeld, R., Townsley, F., & Bienz, M. (2000) · Nature · doi:10.1038/35023016 · Cited by 343 · cited 1×
“These mice produce a short APC (1-580) mutant, which lacks all 20-AARs and is classified as tankyrase inhibitor–sensitive, according to our present study.”
BackgroundA Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth
Lau, T., Chan, E., Callow, M., Waaler, J., Boggs, J., Blake, R. A., Magnuson, S., Sambrone, A., Schutten, M., Firestein, R., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4562 · Cited by 316 · cited 8×
“Tankyrase inhibitor–sensitive colorectal cancer cells retain highly activated Wnt/b-catenin signaling To identify molecular parameters that are associated with cellular sensitivity to tankyrase inhibitors, we first evaluated the growth-inhibitory effects of tankyrase inhibitors G007-LK, IWR-1 and XAV939 (18, 20, 22) o…”
BackgroundInfluential
Cited by
Wnt/β-catenin signaling in cancers and targeted therapies
Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00701-5 · Cited by 734
“These results suggested an underlying therapeutic value of Tnks for dealing with truncated Apc mutant cancers.(329) XAV939 was identified as an inhibitory factor of Wnt/β-catenin signaling, originally in CRC cell lines.”
BackgroundMutations and mechanisms of WNT pathway tumour suppressors in cancer
Bugter, J. M., Fenderico, N., & Maurice, M. M. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00307-z · Cited by 466
WNT as a Driver and Dependency in Cancer
Parsons, M. J., Tammela, T., & Dow, L. E. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0190 · Cited by 257
Regulation of Wnt/β‐catenin signalling by tankyrase‐dependent poly(ADP‐ribosyl)ation and scaffolding
Mariotti, L., Pollock, K., & Guettler, S. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14038 · Cited by 144
“Importantly, tankyrase inhibition limits the proliferation of these cells in cell culture (for G007-LK and IWR-1) and xenograft (for G007-LK) models (Lau et al., 2013; Tanaka et al., 2017).”
BackgroundInfluential
Metadata
- Authors
- Tanaka, N., Mashima, T., Mizutani, A., Sato, A., Aoyama, A., Gong, B., Yoshida, H., Muramatsu, Y., Nakata, K., Matsuura, M., Katayama, R., Nagayama, S., Fujita, N., Sugimoto, Y., & Seimiya, H.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2017-04-01
- Volume
- 16
- Issue
- 4
- Pages
- 752-762
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2586963023
- Cited by
- 81
- References
- 6
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer. https://app.cochat.ai/papers/10.1158/1535-7163.mct-16-0578
- The paper
- Tanaka, N., Mashima, T., Mizutani, A., Sato, A., Aoyama, A., Gong, B., Yoshida, H., Muramatsu, Y., Nakata, K., Matsuura, M., Katayama, R., Nagayama, S., Fujita, N., Sugimoto, Y., & Seimiya, H. (2017). APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-16-0578
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.